California firm looks to Israel for personalized cannabinoid approach
The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.
California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.
Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.
Both compounds employ an “FDA-approved synthetic THC.”
Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.
CMAJ commentary argues for two-stream cannabis system
Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.
In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."
The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”
U.S.-German-Israeli deal links cancer diagnostics with cannabinoids
MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”
Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.
SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.
Cannabics’ R&D facility is “concentrated” in Israel.
Data on CBD analogue to be presented at neuroscience meeting
Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.
The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”
The firm will also present data on the anti-addictive potential of NB2222.
"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.
Yesterday, Oct 17, 2018, officially became Canada’s cannabis legalization day. Craig Ex aka The Expert of Expert Joints went to Victoria, the capital of BC, with Kyle from High Times to celebrate the big day on the grounds of the provincial legislature. Waking up, there was a ...
This week Craig welcomes back Criminal Defence Lawyer Sarah Leamon, and samples products from Weeds Glass & Gifts. He also has music from Burnalotta Endo during Dab Time with Tha Big Puffa, gets Grow Tips from Dawgo The Hutt… and brings you a new Chronic Cooking video too. Joi...
Marijuana is officially legal in Canada. As of today, it is no longer a criminal offense for adults at least 18 years of age to possess, use and grow weed at home for personal use. It is a scene that is expected to generate billions of dollars in economic reach for the nation, e...
Cannabis sector investors looking for a strong operator with exposure to the U.S. market should take a long look at Trulieve Cannabis Corp.(Trulieve Cannabis Stock Quote, Chart CSE:TRUL), says GMP Securities analyst Robert Fagan. In a research report to clients Wednesday, Fagan ...
Marijuana may be a Canadian obsession right now, but don’t expect your local Starbucks to be offering a bit of bud with your latte anytime soon. That’s according to CEO Kevin Johnson, who says that weed culture just doesn’t fit in with the Starbucks brand. It’s Happy Can...
Today, Canada’s legal federal cannabis industry came online, marking a historic moment for the cannabis movement. However, not everyone is excited about the government’s new regulations. For one, the federal government’s cannabis regulations that are now in effect don’t ...
Grab your credit card, get ready to rip open your bag of Doritos and click on that Ontario Cannabis Store webpage bookmark you made months ago, ’cause as of 12:01 a.m., weed is legal in Canada. Here in Ontario, the only way to purchase marijuana is through OCS.ca — a gover...
This morning, legal cannabis finally becomes a reality in Canada, as the Cannabis Act has finally taken effect. However, a policy patchwork across the country’s provinces and ongoing political tussles have left many confused as to what Canada’s new legal cannabis system will...
The S&P 500 fell to its lowest level since early July and pierced its 200-day moving average last week. Chartists looking for stocks that held up better during this decline can use these levels for comparison. Stocks that did not break below their August lows and 200-day moving ...